Since 2021, aggregated from related topics
Triple negative breast cancer is a subtype of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This aggressive form of breast cancer often occurs in younger women, African-American women, and those with a BRCA1 mutation. Triple negative breast cancer is not responsive to hormonal therapies or treatments that target HER2, making it more difficult to treat compared to other types of breast cancer. Research in this area focuses on finding new treatment strategies and identifying biomarkers that can predict response to therapy in order to improve patient outcomes.